Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30339079 | 0.99 | CHRNB2 (0.33) | CHRNB2CHRNA4DPP4DPP8DPP7 | |
| Trifluoroacetic Acid SCHEMBL30338672 | 0.99 | CHRNB2 (0.33) | CHRNB2CHRNA4DPP4DPP8DPP7 | |
| Trifluoroacetic Acid SCHEMBL30581170 | 0.99 | CHRNB2 (0.33) | CHRNB2CHRNA4DPP4DPP8DPP7 | |
| SCHEMBL29048263 | 0.84 | CHRNB2 (0.32) | CHRNB2CHRNA4 | |
| SCHEMBL25816376 | 0.84 | CHRNB2 (0.32) | CHRNB2CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL31205907 | 0.84 | HDAC4 (0.37) | CHRNB2CHRNA4HCAR2CHRNA3CHRNB3 | |
| Trifluoroacetic Acid SCHEMBL30339058 | 0.84 | HDAC4 (0.37) | CHRNB2CHRNA4HCAR2CHRNA3CHRNB3 | |
| Hydrochloric Acid SCHEMBL29048286 | 0.83 | CHRNB2 (0.32) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL29048250 | 0.83 | CHRNB2 (0.32) | CHRNB2CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL30338923 | 0.83 | HDAC4 (0.36) | CHRNB2CHRNA4HCAR2CHRNA3CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| EP-4157835-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | CHRNB2 4268/4885CHRNA4 3645/4885DPP4 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.